Celltrion saw the highest growth of 2.99% in patent filings in May and 4.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.32% and grants by 4.99%. GlobalData’s DataBook provides a comprehensive analysis of Celltrion‘s patent filings and grants. Buy the databook here.
Celltrion has been focused on protecting inventions in South Korea(KR) with two publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings with nearly 50% of filings. The South Korea(KR), Denmark(DK), United States(US), and Australia(AU) patent Office are among the top ten patent offices where Celltrion is filings its patents. Among the top granted patent authorities, Celltrion has 20% of its grants in United States(US) and 10% in Australia(AU).
Regeneron Pharmaceuticals could be the strongest competitor for Celltrion
Patents related to cybersecurity and cloud lead Celltrion's portfolio
Celltrion has the highest number of patents in cybersecurity followed by, cloud. For cybersecurity, nearly 75% of patents were filed and no patents were granted in Q2 2024.
Ileitis related patents lead Celltrion portfolio followed by ulcerative colitis, and psoriasis
Celltrion has highest number of patents in ileitis followed by ulcerative colitis, psoriasis, rheumatoid arthritis, and sepsis.
For comprehensive analysis of Celltrion's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.